Theranostics for Cancer Therapy

Shanbhag, Pradnya Palekar; Jog, Sneha V.; Chogale, Manasi; Gaikwad, Sujata S.

doi:10.2174/1567201811310030013

Cited by 56 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NPs offer an attractive platform for development of so-called theranostic agents, which combine therapy and diagnosis with the aim of reducing the need for multi-step procedures and avoiding treatment delays [102]. Antibody targeting has a major role to play in this field (Figure 4), and SPIONs have become the most advanced theranostic NPs using a range of innovative approaches.…”

Section: Antibody-conjugated Nanoparticles As Theranostic Agentsmentioning

confidence: 99%

Antibody-Targeted Nanoparticles for Cancer Treatment

2016

View full text Add to dashboard Cite

Nanoparticles are diverse and versatile with physical properties that can be employed for use in cancer medicine. Targeting nanoparticles using antibodies and antibody fragments could overcome some of the limitations seen with current targeted therapies. This review will discuss the role of antibody-targeted nanoparticles in the treatment of cancer: as delivery vehicles, targeted theranostic agents and in the evolving field of cancer hyperthermia.

show abstract

Section: Antibody-conjugated Nanoparticles As Theranostic Agentsmentioning

confidence: 99%

Antibody-Targeted Nanoparticles for Cancer Treatment

2016

View full text Add to dashboard Cite

show abstract

“…An emerging trend in the clinical implementation of multifunctional pharmaceutics is theranostics, a combined diagnostic and therapeutic approach designed to eliminate multi-step procedures, reduce delays in treatment, and facilitate patient care overall (31). Recently, a bispecific antibody known as Blincyto (blinatumomab, AMGEN) was approved by the Food and Drug Administration (FDA) for treating B-cell acute lymphoblastic leukemia.…”

Section: Discussionmentioning

confidence: 99%

Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer

Luo

England

Shi

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose Pancreatic adenocarcinoma is a highly aggressive cancer, currently treated with limited success and dismal outcomes. New diagnostic and treatment strategies offer the potential to reduce cancer mortality. Developing highly-specific non-invasive imaging probes for pancreatic cancer is essential to improving diagnostic accuracy and monitoring therapeutic intervention. Experimental Design A bispecific heterodimer was synthesized by conjugating an anti-tissue factor (TF) Fab with an anti-CD105 Fab, via the bioorthogonal “click” reaction between tetrazine (Tz) and trans-cyclooctene (TCO). The heterodimer was labeled with 64Cu for positron emission tomography (PET) imaging of nude mice bearing BXPC-3 xenograft and orthotopic pancreatic tumors. Results PET imaging of BXPC-3 (TF/CD105+/+) xenograft tumors with 64Cu-labeled heterodimer displayed significantly enhanced tumor uptake (28.8 ± 3.2 %ID/g; n = 4, SD) at 30 h post-injection (p.i.), as compared to each of their monospecific Fab tracers (12.5 ± 1.4 and 7.1 ± 2.6 %ID/g; n = 3, SD). In addition, the activity-concentration ratio allowed for effective tumor visualization (tumor/muscle ratio 75.2 ± 9.4 at 30 h p.i.; n = 4, SD). Furthermore, 64Cu-NOTA-heterodimer enabled sensitive detection of orthotopic pancreatic tumor lesions with an uptake of 17.1 ± 4.9 %ID/g at 30 h p.i. and tumor/muscle ratio of 72.3 ± 46.7. Conclusions This study demonstrates that dual targeting of TF and CD105 provided synergistic improvements in binding affinity and tumor localization of the heterodimer. Dual-targeted imaging agents of pancreatic and other cancers may assists in diagnosing pancreatic malignancies as well as reliable monitoring of therapeutic response.

show abstract

“…The word theranostics designates the synergistic combination of therapy and diagnostic. Theranostic approaches aim at eliminating multi‐step procedures as well as reducing treatment delays, and have gained a lot of relevance over the last years , . As previously mentioned in this review, the bioactivity of POMs has been studied for more than five decades.…”

Section: Polyoxometalate Composites For Cancer Theranosticsmentioning

confidence: 99%

Polyoxometalate Composites in Cancer Therapy and Diagnostics

et al. 2020

View full text Add to dashboard Cite

Polyoxometalates (POMs) are metal‐oxide inorganic clusters, mostly anionic, where the metal is usually a transition metal (such as V, W, or Mo). Owing to their great variety of structures and large range of molecular dimensions, POMs have attracted considerable attention over the years. The high solubility in water together with the extent of their redox chemistry make POMs and their composites very versatile materials that find many applications in the biomedical field such as drug delivery systems or anti‐viral and anti‐tumoural agents. While the antitumoural activity of POMs and their derivatives is well documented, their application in emergent cancer therapies has not been addressed. This review presents the application of POM‐based composites as photothermal agents, radiosensitisers, and biosensors. The latest advances in the design of novel POM nanocomposites for cancer theranostics are also highlighted.

show abstract

Theranostics for Cancer Therapy

Cited by 56 publications

References 0 publications

Antibody-Targeted Nanoparticles for Cancer Treatment

Antibody-Targeted Nanoparticles for Cancer Treatment

Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer

Polyoxometalate Composites in Cancer Therapy and Diagnostics

Contact Info

Product

Resources

About